Valuation: MBX Biosciences, Inc.

Market Cap 2.77B 2.44B 2.3B 2.09B 3.93B 266B 3.95B 27.59B 10.66B 136B 10.4B 10.18B 436B P/E 2026 *
-18.5x
P/E 2027 * -14.2x
Enterprise Value 2.26B 1.99B 1.88B 1.71B 3.2B 217B 3.22B 22.51B 8.69B 111B 8.49B 8.3B 356B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.18%
Yield 2026 *
-
Yield 2027 * -
1 day+7.29%
1 week-5.58%
Current month-6.59%
1 month-8.67%
3 months+10.00%
6 months+101.89%
Current year+82.44%
1 week 52.32
Extreme 52.32
61.85
1 month 52.32
Extreme 52.32
65
Current year 26.14
Extreme 26.14
72.64
1 year 12.94
Extreme 12.94
72.64
3 years 4.81
Extreme 4.8069
72.64
5 years 4.81
Extreme 4.8069
72.64
10 years 4.81
Extreme 4.8069
72.64
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-12
Director of Finance/CFO 73 2026-02-28
Chief Tech/Sci/R&D Officer - 2025-06-22
Director TitleAgeSince
Director/Board Member 66 2020-06-30
Director/Board Member 55 2020-06-30
Director/Board Member 69 2022-04-04
Date Insider Type Main position Quantity % Market Cap. Importance
8/4/26 Sell

Chief Technology Officer

-370 0.0008%
8/3/26 Free

Chief Financial Officer

158,000 0.3281%
8/3/26 Free

Chief Executive Officer

402,000 0.8347%
Change 5-day change 1-year change 3-year change Capi.($)
+7.29%-5.58%+228.61% - 2.58B
+2.64%+6.45%+11.87%+38.40% 47.97B
+0.22%+0.40%+50.91%+37.06% 44.5B
-1.58%+4.66%+359.34%+614.38% 43.93B
+1.70%+0.36%+12.56%+99.27% 41.03B
+0.51%-1.71%+5.18%+46.87% 29.85B
-0.48%-1.32%+23.98%+150.01% 17.27B
+0.08%+9.03%+8.41% - 15.34B
+1.76%+0.85%+29.13%+48.42% 15.3B
+1.97%-3.17% - - 14.82B
Average +1.41%+0.91%+81.11%+147.77% 27.26B
Weighted average by Cap. +0.81%+1.82%+80.96%+163.79%

Financials

2026 *2027 *
Net sales - -
Net income -151M -133M -125M -114M -213M -14.46B -215M -1.5B -579M -7.38B -566M -553M -23.72B -220M -194M -183M -166M -312M -21.12B -314M -2.19B -846M -10.78B -826M -808M -34.63B
Net Debt -511M -449M -425M -385M -723M -49.02B -728M -5.09B -1.96B -25.01B -1.92B -1.88B -80.38B -418M -368M -348M -316M -593M -40.16B -596M -4.17B -1.61B -20.49B -1.57B -1.54B -65.85B
Logo MBX Biosciences, Inc.
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency.
Employees
63
Date Price Change Volume
26-09-28 US$57.54 +7.29% 439,560
26-09-25 US$53.63 -3.18% 563,530
26-09-24 US$55.39 -4.32% 638,966
26-09-23 US$57.89 -6.60% 352,410
26-09-22 US$61.98 +1.71% 433,367
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
57.54USD
Average target price
88.10USD
Spread / Average Target
+53.11%

Quarterly revenue - Rate of surprise